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Liver transplantation numbers in the United States re-
mained constant from 2004 to 2007, while the num-
ber of waiting list candidates has trended down. In
2007, the waiting list was at its smallest since 1999,
with adults ≥50 years representing the majority of
candidates. Noncholestatic cirrhosis was most com-
monly diagnosed. Most age groups had decreased
waiting list death rates; however, children <1 year
had the highest death rate. Use of liver allografts
from donation after cardiac death (DCD) donors in-
creased in 2007. Model for end-stage liver disease
(MELD)/pediatric model for end-stage liver disease
(PELD) scores have changed very little since 2002,
with MELD/PELD <15 accounting for 75% of the wait-
ing list. Over the same period, the number of trans-
plants for MELD/PELD <15 decreased from 16.4% to
9.8%. Hepatocellular carcinoma exceptions increased
slightly. The intestine transplantation waiting list de-
creased from 2006, with the majority of candidates be-
ing children <5 years old. Death rates improved, but
remain unacceptably high. Policy changes have been
implemented to improve allocation and recovery of in-
testine grafts to positively impact mortality. In addition
to evaluating trends in liver and intestine transplanta-
tion, we review in depth, issues related to organ ac-
ceptance rates, DCD, living donor transplantation and
MELD/PELD exceptions.
Key words: Deceased donors, living donors, organ
donation, organ procurement, Scientific Registry of
Transplant Recipients
Introduction
The introduction of the model for end-stage liver disease
(MELD) and the pediatric model for end-stage liver disease
(PELD) on February 27, 2002, as the basis for allocation
of deceased donor livers for transplantation in the United
States (US) has transformed the field of liver transplan-
tation. The use of this urgency-based allocation system
appears to have reduced the number of candidates listed
annually while allowing more rational and objective alloca-
tion based on risk of waiting list mortality. Equally impor-
tant, the use of MELD and PELD has helped frame the
central role that medical urgency deserves, both regard-
ing the decision to transplant a given patient, as well as in
allocation policy.
In this report, we review trends in liver and intestine
transplantation over the last decade using data from the
2008 Organ Procurement and Transplantation Network
(OPTN)/Scientific Registry of Transplant Recipients (SRTR)
Annual Report. Details on the methods of analyses em-
ployed may be found in the reference tables themselves
or in the technical notes of the 2008 OPTN/SRTR Annual
Report, both available from http://www.ustransplant.org.
This article focuses on specific areas of interest to the
transplant community through analyses presented by the
SRTR to the OPTN committees as well as special analy-
ses conducted specifically for this manuscript. In addition
to reviewing trends in the waiting list, deceased and living
donor transplant recipients and posttransplant outcomes,
special sections are included on issues related to organ ac-
ceptance rates, donation after cardiac death (DCD), living
donor transplantation and MELD/PELD exceptions. An in-
depth examination of the state of intestine transplantation
is also provided.
Liver Waiting List
There were 12 213 patients active on the liver transplant
waiting list on December 31, 2007, a decrease from 2006




























Source: 2008 OPTN/SRTR Annual Report, Table 9.1a.
Figure 1: Number of candidates on
the liver waiting list, active at year-
end, 1998–2007.
1999, when there were 12 044 patients on the waiting
list at the year’s end. New registrations increased from
11 036 in 2006 to 11 081 in 2007, but the number of
inactive patients on the waiting list has remained stable
at around 4200 for the past 5 years. All of the waiting list
characteristics are based on a snapshot of the list on the
last day of the calendar year.
Age, race/ethnicity, gender and blood type: The liver
waiting list continued its aging trend in 2007, with adults
aged 50 years and older representing 74% of the wait-
ing list, compared with 72% in 2006 and 51% in 1998
[Table 9.1a]. Pediatric candidates remained at 3% of the
list, the same as 2006, compared with 6% in 1998. A simi-
lar trend was observed for younger adults. The racial/ethnic
distribution of the waiting list has remained stable for the
past 5 years. In 2007, there were 71.4% white, 6.8%
African American, 16.5% Hispanic, 4.5% Asian American
and 0.8% other. Similar to past years, in 2007, men out-
numbered women on the waiting list (males: 60%, fe-
Table 1: Liver waiting list candidates (active at end of year) by diagnosis, 1998–2007
1998 1999 2000 2001 2002 2003 2004 2005 2006 2007
Noncholestatic cirrhosis (%) 70 70 70 70 70 71 72 72 73 73
Hepatitis C (%) 28 29 29 30 30 31 31 31 31 30
Alcoholic cirrhosis (%) 15 15 15 15 15 15 15 15 16 16
Both hep C & alcoholic (%) 8 8 7 6 7 6 7 7 6 7
Autoimmune hepatitis (%) 4 4 4 4 5 4 4 4 4 4
Hepatitis B only (%) 4 4 4 4 3 4 3 3 3 3
Cryptogenic/idiopathic/NASH (%) 10 10 9 10 10 10 10 11 11 12
Other noncholestatic (%) 1 1 1 1 1 1 1 1 1 1
Cholestatic liver disease (%) 13 12 12 11 11 11 11 11 10 10
Acute hepatic necrosis (%) 4 5 5 5 5 5 4 4 4 3
Biliary atresia (%) 2 2 2 2 2 2 2 2 1 1
Metabolic disorders (%) 2 2 2 2 2 1 2 2 1 1
Malignant neoplasms (%) 1 1 1 1 1 1 1 1 2 2
Other (%) 7 8 8 9 9 9 8 9 9 9
Candidates with both hepatitis B and hepatitis C are counted in the hepatitis C category. NASH = nonalcoholic steatohepatitis.
males: 40%). Blood type distribution among waiting list
candidates was also similar to previous years: 49% had
blood type O; 38% had blood type A; 11% had blood type
B and 2% had blood type AB. There were fewer females
and blood type O candidates in 2007 compared with pre-
vious years.
Primary diagnosis at listing and previous transplant:
The distribution of major diagnostic categories of liver dis-
ease in 2007 was similar to previous years (Table 1). Non-
cholestatic cirrhosis was the diagnosis for 73% of waiting
list candidates, the largest diagnostic category [Table 9.1a].
Cholestatic cirrhosis at 10% was the second largest, fol-
lowed by other with 9%, acute hepatic necrosis with
3%, malignant neoplasms with 2% and biliary atresia and
metabolic diseases each accounting for less than 2% of
the waiting list. These categories are determined by the
primary diagnosis code listed for each candidate; so, the
malignant neoplasms group contains candidates with hep-
atocellular carcinoma (HCC) and other liver cancers only
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Source: 2008 OPTN/SRTR Annual Report, Table 9.1a.
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Figure 2: Distribution of MELD/
PELD scores among candidates on
the liver waiting list at year-end,
2003–2007.
if these conditions were listed as the primary diagno-
sis. Note that candidates with MELD/PELD exceptions for
HCC often do not have a diagnosis of HCC; only 21% of
candidates with initial applications for the HCC MELD/
PELD exception in 2006 had a primary diagnosis of ma-
lignant neoplasm, while 59% had a primary diagnosis of
noncholestatic cirrhosis. The OPTN/SRTR registry data do
not contain a data field where all liver transplant candidates
have the presence or absence of HCC reported; informa-
tion on HCC in the registry data can come from either the
diagnosis codes or the application for a MELD/PELD ex-
ception score. Three percent of waiting list candidates had
a previous liver transplant in 2007, a decrease from 5% in
the late 1990s.
MELD/PELD scores: Adult waiting list MELD scores
changed very little since the implementation of
MELD/PELD in 2002 (Figure 2) [Table 9.1a]. Candidates
with MELD scores <15 accounted for 75% of the wait-
ing list at the end of 2007, a fraction similar to previous
years [Table 9.1a]. A change to allocation policy was imple-
mented on January 12, 2005, which substituted the use
of the PELD score with the MELD score for adolescents
aged 12–17 years. This policy changed the age range of
the PELD candidate group from <18 years old (2002–2004)
to those <12 years old (2005–2006). There were 66% of
PELD candidates with scores <11 in 2005, 62% in 2006
and even fewer in 2007, at 60%. Approximately 2% of chil-
dren on the waiting list had PELD scores >30 in 2007.
Waiting time and median time to transplant: By the
end of 2007, 63% of the waiting list with active status
had been listed for more than 1 year (18% waiting for 1
to <2 years and 45% waiting for 2+ years) [Table 9.1a].
The median time to transplant (TT) among candidates on
the waiting list initially listed in the given calendar year is
shown in Figure 3 [Table 1.5]. The median TT is calculated
as the number of days until half of the new waiting list
registrants in the calendar year have received a transplant.
Median TT for liver waiting list candidates decreased sub-
stantially after the implementation of MELD/PELD in 2002,
when the median TT was 981 days; in 2003, it decreased
to 564 days [Table 1.5]. There was a noticeable drop in
median TT between 2004 (400 days) and 2005 (296 days),
which coincided with several changes in allocation policy,






















Source: 2008 OPTN/SRTR Annual Report, Table 1.5.
Figure 3: Median time to transplant (TT) for new liver waiting
list registrations, 2003–2007.


































Source: 2008 OPTN/SRTR Annual Report, Table 9.3.  
Figure 4: Unadjusted death rates
per 1000 patient-years at risk,
1998–2007, liver waiting list.
adolescents to the MELD score instead of the PELD score
and the implementation of a new MELD survival curve (re-
sulting in the exception for stage T2 HCC decreasing to a
score of 22). Median TT reached a 10-year low of 286 days
in 2006 before increasing again in 2007 to 361 days.
Death rates on the waiting list: Death rates for the wait-
ing list (deaths per 1000 patient-years at risk) declined in
2007 to 113 from 121 in 2006 (Figure 4) [Table 9.3] and var-
ied according to demographic and medical factors. Most
age groups had decreased death rates. In 2005 patients
>65 years had a death rate of 164 and 165 in 2006. In
2007 an improvement was seen with a rate of 129. Chil-
dren <1 year had, by far, the highest rate of all age groups
(447 deaths per 1000 patient-years). While the death rate
in children <1 year remains high, it has declined sharply
from past years (738 in 2005 and 905 in 2006). All eth-
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Figure 5: Unadjusted death rates
per 1000 patient-years at risk,
1998–2007, liver waiting list by
race/ethnicity.
nic groups had declining death rates in the last decade
(Figure 5) [Table 9.3]. Asian Americans had the lowest
death rate on the waiting list at 81 in 2007 (lower than
the 2006 rate of 96). With steady rates of 136–145 over
the past 5 years, Hispanics showed a marked decrease in
death rates at 108 in 2007. The 2007 death rates for African
Americans and whites did not change much from 2006 at
142 and 113, respectively. In 2007, men and women had
the same rate of 113, and both were lower than 2006.
All disease etiologies had decreasing death rates over
the past 10 years when assessed according to diagnos-
tic group. Not surprisingly, in 2007 acute hepatic necrosis
had the highest death rate at 160, down from 2006 when
it was 190 and down two-fold since 1998, likely a result
of regional sharing (introduced in 1997 and 1998) and im-
proved patient selection for placement on the waiting list
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Source: 2008 OPTN/SRTR Annual Report, Table 9.2b. Uses laboratory MELD score.
Figure 6: Waiting list candidates
with events within 30, 60 and 90
days after snapshot (January 1,
2007) by MELD.
[Table 9.3]. The second highest waiting list death rate was
153 for diagnoses classified as other, down slightly from
2006, when it was 166. The remaining categories were:
116 for metabolic disorders; 109 for malignant neoplasms
(this category does not contain all candidates with HCC
exceptions, only those with a primary diagnosis of liver
cancer); 109 for noncholestatic cirrhosis; 80 for cholestatic
cirrhosis and 44 for biliary atresia. The waiting list death
rate was extremely high for candidates listed as Status 1A
at 4364, even though it decreased from 2005 (6158). Given
the ability of MELD and PELD to predict 3-month waiting
list mortality, waiting list death rates increased as MELD
and PELD increased, from 35 for MELD scores 6–10 to
596 for MELD scores 21–30 and 3758 for MELD over 30.
Similarly, waiting list death rates increased as PELD scores
increased, from 11 for PELD <11, to 768 for PELD scores
21–30 and 2064 for PELD greater than 30. Patients with
exceptions for HCC with stage T2 lesions (HCC T2) had a
death rate of 99, down from 133 in 2006. Those with excep-
tions for other diagnoses had a death rate of 81 compared
with 101 in 2006.
Patient events on the waiting list: Figure 6 shows the
incidence of transplant and removal for death, being too
sick or medically unsuitable for transplant over 3 months
for adults on the waiting list, by waiting status on January
1, 2007 [Table 9.2b] (SRTR analysis). Thirty days later, less
than 1% of candidates with MELD scores of 20 or less
on January 1 had either died or were removed as too sick
(0.4%) while 1.4% received transplants [Table 9.2b]. Can-
didates with MELD 21–30 had a removal rate for death or
too sick to transplant of 5.6% and a transplant rate of 19%.
In the highest MELD score group (MELD >30), 29% of pa-
tients died or were removed as too sick to transplant, while
almost half (46%) received transplants within 30 days of
January 1. About one-quarter (26%) of candidates with an
HCC T2 exception on January 1 received transplants within
30 days, while only 1.6% died or were removed from the
list as too sick.
Liver Transplant Recipients
The number of liver transplantation procedures performed
in the US in 2007 decreased to 6489 from 6650 in 2006
[Table 9.4a, 9.4b]. Deceased donors accounted for 96%
of transplants, and 4% were from living donors. In 2007
there were 139 fewer deceased donor liver transplants
(DDLT) and 22 fewer living donor liver transplants (LDLT)
performed, compared with 2006. This slight decrease in
the number of transplants was seen across all solid or-
gans, including a decrease in kidney-alone transplants from
16 644 in 2006 to 16 119 in 2007 [Table 1.7]. However, the
number of combined liver–kidney transplants increased to
444 in 2007 compared with 400 in 2006 [Table 1.8].
Age: Figure 7 shows the age distribution of DDLT recipi-
ents for the past 10 years [Table 9.4a]. Pediatric (less than
18 years of age) DDLT recipients were only 9% of all DDLT
in 2007, and numbers for this group have changed very
little (7% for children under 12 years and 2% for children
aged 12–17 years). Adult DDLT recipients aged ≥50 years
had the largest increase in DDLT since 1998, matched by
decreases in the younger adult categories over the years.
LDLT recipients have decreased in numbers since a peak
of 522 transplants in 2001 (Figure 8) [Table 9.4b]. The
change in age distribution among LDLT recipients is con-
siderably different from DDLT recipients. The majority of
LDLT cases in 1998 were pediatric recipients (73%), but
by 2007, recipients under age 18 years were only 26% of
the total, reflecting expansion of adult-to-adult LDLT. Can-
didates aged 50–64 years (35%) received the most LDLT in
2007.
Gender, race/ethnicity, blood type and residence: De-
mographic factors such as gender, race/ethnicity and blood
type among DDLT recipients in 2007 were very similar to
the waiting list. Men received more liver transplants in
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Source: 2008 OPTN/SRTR Annual Report, Table 9.4a.
Figure 7: Number of deceased
donor liver transplants by age,
1998–2007.
2007 than women [Table 9.4a], although in 2007, as in
2006, a higher proportion of LDLT were women (42%)
than DDLT (33%) [Table 9.4b]. DDLT among racial groups
in 2007 was also similar to 2006 with 70% white, 14%
Hispanic, 10% African Americans and 5% Asian. Blood
group distribution among DDLT was again similar to previ-
ous years; however, in 2007 a higher proportion of LDLT
went to blood type B recipients (12%) compared with 2006
(9%). From 1998 to 2007, fewer DDLT were performed for
non-resident aliens (1.9% in 1998 and <1% in 2007).
Insurance: Very little has changed from 2006 to 2007
in primary source of payment among DDLT recipients
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Source: 2008 OPTN/SRTR Annual Report, Table 9.4b.
Figure 8: Number of living donor
liver transplants by age, 1998–
2007.
of DDLT recipients (58%), while Medicare paid for 21%
and Medicaid paid for 16%. Alternative payment methods
accounted for 5% of DDLT recipients. Private insurance
was more common for LDLT recipients at 74%, compared
with DDLT recipients. Fewer LDLT recipients had Medicare
(11%) or Medicaid (9%) coverage [Table 9.4b].
Previous transplant: In 2007, DDLT recipients that had
undergone a previous liver transplant decreased to 7.8%
from 8.6% in 2006, the lowest proportion of the decade.
There were no LDLT recipients in 2007 with a previous
liver transplant, down from a high of 17 in 1999, reflecting
challenges and poorer outcomes associated with LDLT in
retransplant recipients [Table 9.4b].
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Table 2: Liver deceased donor transplant recipients by diagnosis, 1998–2007
1998 1999 2000 2001 2002 2003 2004 2005 2006 2007
Noncholestatic cirrhosis (%) 63 64 64 64 62 59 60 61 59 57
Hepatitis C (%) 24 26 28 28 29 27 27 24 23 22
Alcoholic cirrhosis (%) 13 13 12 11 11 12 11 12 11 11
Both hep C & alcoholic (%) 8 8 7 8 5 5 6 8 7 7
Autoimmune hepatitis (%) 4 3 4 3 3 3 2 3 2 2
Hepatitis B only (%) 4 4 3 4 4 3 3 2 2 2
Cryptogenic/idiopathic/ NASH (%) 9 9 9 8 7 8 9 10 10 11
Other noncholestatic (%) 1 1 1 1 1 1 2 3 2 2
Cholestatic liver disease (%) 13 11 10 10 10 10 9 8 9 9
Acute hepatic necrosis (%) 8 9 9 8 7 7 7 7 6 6
Biliary atresia (%) 5 4 4 4 3 3 3 3 2 3
Metabolic disorders (%) 4 3 4 4 3 3 3 3 3 3
Malignant neoplasms (%) 2 2 2 3 7 7 8 10 12 13
Other (%) 6 6 7 8 7 11 9 8 9 10
Recipients with both hepatitis B and hepatitis C are counted in the hepatitis C category. NASH = nonalcoholic steatohepatitis.
Diagnosis: As in 2006, noncholestatic cirrhosis was most
commonly diagnosed in 2007 for both DDLT and LDLT.
Among DDLT recipients, 57% were primarily diagnosed
with noncholestatic cirrhosis in 2007, a slight decrease
from 59% in 2006 (Table 2) [Table 9.4a]. The second
most common diagnosis among DDLT recipients was ma-
lignant neoplasms, which remained stable at 13% (this
group contains only those recipients that had liver can-
cer listed as their primary diagnosis and does not in-
clude all HCC MELD/PELD exception holders). The remain-
ing diagnostic categories were: other diagnoses (10%);
cholestatic liver disease (9%); acute hepatic necrosis (6%);
metabolic disorders (3%) and biliary atresia (3%). LDLT re-
cipient diagnoses differed greatly from those of DDLT re-
cipients (Table 3). Noncholestatic cirrhosis accounted for
only 39% of LDLT recipients, remaining stable from 2006
[Table 9.4b]. The second most common diagnosis was
cholestatic cirrhosis at 18%, down from 23% in 2006. Sim-
ilar to last year, the remaining diagnosis categories were:
12% for other (8% in 2006); 12% for malignant neoplasms
(9% in 2006); 12% for biliary atresia (12.5% in 2006); 4%
Table 3: Liver living donor transplant recipients by diagnosis, 1998–2007
1998 1999 2000 2001 2002 2003 2004 2005 2006 2007
Noncholestatic cirrhosis (%) 22 38 44 56 52 46 50 46 39 39
Hepatitis C (%) 9 21 24 27 28 23 22 20 15 17
Alcoholic cirrhosis (%) 3 4 6 8 8 8 9 9 6 5
Both hep C & alcoholic (%) 1 3 2 4 4 2 3 4 3 2
Autoimmune hepatitis (%) 5 4 2 4 3 2 4 2 2 3
Hepatitis B only (%) 1 3 1 3 3 2 1 2 2 2
Cryptogenic/idiopathic/NASH (%) 2 5 8 7 6 9 11 8 11 9
Other noncholestatic (%) 0 0 0 1 1 1 0 1 0 1
Cholestatic liver disease (%) 7 11 18 16 21 21 23 21 23 18
Acute hepatic necrosis (%) 7 10 6 5 4 7 3 4 6 3
Biliary atresia (%) 42 20 14 9 9 12 7 8 13 12
Metabolic disorders (%) 5 5 4 3 2 2 3 3 2 4
Malignant neoplasms (%) 2 9 8 6 5 3 7 8 9 12
Other (%) 15 7 7 6 6 8 8 10 8 12
Recipients with both hepatitis B and hepatitis C are counted in the hepatitis C category. NASH = nonalcoholic steatohepatitis.
for metabolic disorders (2% in 2006) and 3% for acute
hepatic cirrhosis (6% in 2006).
Medical condition: Slightly fewer patients were in the
intensive care unit (ICU) at the time of their DDLT (13%) in
2007 compared with 2006 (14%). There has been a stable
trend in the past 10 years toward a reduction of hospi-
talized and ICU-bound candidates at the time of transplant
(Figure 9) [Table 9.4a]. Candidates emergently transplanted
with deceased donor livers in the Status 1/1A category
declined from 11% in 1998 to 6% in 2007. Of all DDLT
candidates, only 66 (1.1% of all DDLT) were transplanted
as Status 1B (implemented in late August 2005), up from
44 in 2006. Of note, Status 1B is restricted to patients in
the pediatric population. Consistent with policies designed
to direct more organs to higher MELD patients, such as
Share 15, higher proportions of DDLT are going to candi-
dates with higher MELD scores, and fewer transplants are
performed for candidates with MELD <15. Similar to 2006,
only 8.5% of DDLT were for patients without exceptions
with MELD 6–14. The pediatric DDLT patient distribution
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Source:  2008 OPTN/SRTR Annual Report, Table 9.4a.
Figure 9: Deceased donor trans-
plant recipients by hospitalization
status, 1998–2007.
remained relatively unchanged with the highest proportion
consistently in the PELD <11 category. For patients with
HCC exceptions, transplantation increased slightly in 2007
to 15%, up from 14% in 2006.
In 2007, 2% of LDLT (six cases) were performed for pa-
tients on mechanical support, compared with 6% for DDLT
[Table 9.4b]. Six percent of LDLT recipients were in the ICU
(roughly half that of DDLT at 13%) and 14% were hospi-
talized but not in intensive care compared with 17% for
DDLT. Candidates with MELD scores <15 in 2007 were
30% of LDLT, a decrease from 44% in 2006. Patients with
MELD >20 were 10% of all LDLT, up from 2006 (6%),
while patients with HCC exceptions were up from 3% in
2006 to 6%. Only seven LDLT recipients had never been
on the deceased donor transplant waiting list.
Partial liver grafts and ischemia time for DDLT: The
number of partial or split liver transplants among DDLT re-
cipients was 4–5% from 1998 to 2005. In 2006 it dropped
to 2.8% but increased to 3.8% in 2007 [Table 9.4a]. Still,
there were only 235 DDLT performed with split livers in
2007. The trend toward shorter cold ischemia time re-
mained steady from 1998 to 2007. More DDLT were done
with less than 11 hours cold ischemia time (82%) in 2007
compared with years past. Between 1998 and 2007, the
fraction of DDLT performed with less than 6 hours of cold
ischemia time increased from 17% to 29%, while cold is-
chemia time between 11 and 15 hours decreased from
16% to 7%.
Liver Transplant Recipient Survival
Adjusted patient survival following DDLT was 94% at 3
months, 87% at 1 year, 73% at 5 years and 59% at 10 years
[Table 9.12a]. Survival rates were adjusted for recipient
age, gender, race and diagnosis. Adjusted patient survival
for LDLT recipients was 96% at 3 months, 92% at 1 year,
78% at 5 years and 71% at 10 years [Table 9.12b]. Graft
survival for DDLT was 90% at 3 months, 82% at 1 year,
68% at 5 years and 53% at 10 years [Table 9.8a]. Graft
survival for LDLT recipients was 92% at 3 months, 85% at
1 year, 71% at 5 years and 62% at 10 years [Table 9.8b].
Note that the adjustments for these models do not account
for the health of the patients prior to transplant. The greater
survival of living donor transplant recipients likely reflects
their better health at transplant.
Age: Adjusted patient survival varied according to the
recipient’s age. Patient survival for DDLT recipients at
3 months was highest for adults aged 35–49 years at
96%, followed by adolescents aged 12–17 years at 94%
[Table 9.12a]. Children <1 year old had the lowest 3-month
survival rate at 88%. One-year adjusted patient survival for
DDLT recipients was lowest for those aged 65 years and
older at 81%, followed by children <1 year at 83%. The
highest 1-year survival was 90% for all ages between 1
and 50 years. At 5 years, children <1 year old had the
highest survival rate for DDLT at 84%. Older recipient age
remained strongly associated with poorer long-term out-
comes. The lowest 5-year posttransplant survival was for
adults ≥65 years at 64%, with those aged 50–64 years
having the next lowest survival rate at 71%. This trend
is more pronounced for 10-year survival with higher rates
for those transplanted as children (77% for <1 year, 79%
for 1–5 years and 81% for 6–11 years) compared with
younger adults (66% for 12–34 years and 62% for 35–49
years). Older adults aged 50–64 years had the lowest 10-
year survival at 56% and 42% for those ≥65 years. Among
LDLT recipients, patients <1 year and ≥65 years had the
lowest 3-month survival at 94% [Table 9.12b]. LDLT re-
cipients aged 1–5 years had the lowest survival rate of
84% at 1 year, followed by adults ≥50 years at 85%.
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Source:  2008 OPTN/SRTR Annual Report, Tables 9.12a and 9.12b.
Figure 10: Adjusted 5-year patient
survival of LDLT and DDLT recipi-
ents by diagnosis.
Adult LDLT recipients aged 35–49 years demonstrated the
highest 1-year survival at 98%. However, there were too
few transplants to calculate 3-month or 1-year survival for
recipients aged 6–11 and 12–17 years. Survival at 5 years
after LDLT was highest for both children <1 year old and
adults aged 18–34 years at 85% and lowest for those ≥65
years at 71%. At 10 years posttransplant, LDLT recipients
aged 35–49 years appear to have the lowest survival rate.
However, this estimate is very imprecise with a standard
error of 14.6% and is not statistically different than the sur-
vival rate of 54% for those ≥65 years. The highest survival
rates at 10 years were for the youngest age groups: 82%
for <1 year old at transplant, 80% for those aged 1–5 years
and 83% for those aged 6–11 years.
Race/ethnicity and gender: DDLT survival was not sta-
tistically significantly different across race/ethnicity at 3
months or at 1 year. However, 1-year survival for both
Asians (89%) and Hispanics (88%) was higher than for
African Americans (85%) [Table 9.12a]. At 5 years, African
American DDLT recipients had the lowest survival rate
(66%) and Asians and Hispanics had the highest (77% for
Asians and 75% for Hispanics; not statistically different,
p = 0.167). African American DDLT recipients had signifi-
cantly lower survival at 10 years following transplant than
the other racial groups at 50% compared with 59% for
whites, 61% for Hispanics, 68% for Asians and 60% for
other race. Ten-year survival for Asian recipients of DDLT
was statistically significantly higher than all the other racial
groups. Among LDLT, Asians had the highest survival at
3 months (100%) but the remaining race categories were
not statistically different from each other at 3 months (95–
96%) [Table 9.12b]. Survival at 1 year was not statistically
different among racial groups. At 5 years, both Hispan-
ics (84%) and other race (92%) exhibited survival rates
higher than whites (76%), while Asians (80%) had higher
ten-year survival than whites (70%) and African Americans
(68%). Men and women DDLT recipients had similar sur-
vival rates, though statistically significantly different at 3
months (men: 94% vs. women: 92%; p < 0.001) and at 1
year (men: 88% vs. women: 86%; p = 0.004) [Table 9.12a].
Five- and 10-year survival rates were not statistically differ-
ent for men and women. Survival rates for LDLT recipients
only differed by gender for one-year survival with men at
89% and women at 94% (p = 0.03) [Table 9.12b].
Medical factors: At 3 months, adjusted patient survival
for DDLT among primary diagnosis categories was high-
est for cholestatic cirrhosis at 96%; however, biliary atre-
sia at 92% (with a standard error of 2%) and malignant
neoplasms at 95% were not statistically different than
cholestatic cirrhosis [Table 9.12a]. The lowest 3-month sur-
vival was for acute hepatic necrosis at 89%, which was
not statistically different from biliary atresia, metabolic dis-
orders (91% ± 1.6%), or malignant neoplasms. Adjusted
patient survival rates for DDLT at 1 year were 92% for
cholestatic cirrhosis and 87% for noncholestatic cirrhosis
(p = 0.03). Acute hepatic necrosis (84%) and other disor-
ders (83%) did not differ from each other (p = 0.76) but
were statistically significantly lower than cholestatic (p <
0.001 for both) and noncholestatic cirrhosis (p = 0.03 and
p = 0.02, respectively), while malignant neoplasm (87%)
was significantly different from cholestatic cirrhosis only
(p = 0.001). Biliary atresia (89%) and metabolic disorders
(88%) did not differ statistically from any of the other diag-
nostic categories. Adjusted 5-year survival rates according
to diagnostic category for DDLT and LDLT are shown in
Figure 10. DDLT adjusted survival rates at 5 years were
statistically the same for biliary atresia (85%), cholestatic
cirrhosis (82%) and metabolic disorders (80%). Other di-
agnoses (75%) and noncholestatic cirrhosis (72%) were
not statistically different from each other but were sig-
nificantly lower than biliary atresia, cholestatic cirrhosis
and metabolic disorders. Acute hepatic necrosis (70%)
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was lower than other diagnoses (p = 0.01) but not sta-
tistically different than noncholestatic cirrhosis (p = 0.06),
while malignant neoplasm (67%) was significantly lower
than all diagnostic categories except acute hepatic necrosis
(p = 0.19).
For LDLT recipients, adjusted 3-month patient survival was
not statistically different across diagnosis categories ex-
cept that cholestatic cirrhosis (94%) and noncholestatic
cirrhosis (96%) were statistically different from acute hep-
atic necrosis (100%). At 1 year, survival again did not differ
across diagnostic categories except that noncholestatic cir-
rhosis (90%) and malignant neoplasms (87%) differed sta-
tistically from biliary atresia (99%). At 5 years, adjusted
survival for LDLT was statistically the same for biliary
atresia (89%), cholestatic cirrhosis (87%) and other diag-
noses (81%). The other diagnoses category only differed
statistically from malignant neoplasms (55%). Acute hep-
atic necrosis (78%) did not differ statistically from non-
cholestatic cirrhosis (74%), metabolic disorders (70%) and
malignant neoplasms.
Survival among single year cohorts (all recipients of DDLT
and LDLT in a given calendar year) over the previous decade
shows a trend toward improving adjusted patient survival
for each year of DDLT [Table 9.13a]. Three-month adjusted
survival has increased from 91% for those transplanted in
1997 to 95% in 2006. One-year survival for DDLT increased
from 86% in 1997 to 88% in 2002 and has remained level
through 2006, while 3-year survival is the same for those
transplanted in 2004 as it was in 1997. Survival for LDLT
has trended upward, but these improvements are gener-
ally not statistically significant [Table 9.13b]. The number
of people living with a functioning liver transplant contin-
ues to increase demonstrating the impact of successful
liver transplantation [Table 9.16]. Improvements in patient
and graft survival have led to more focus on long-term
outcomes. While such efforts are applicable across all of
liver transplantation, there is a particular emphasis on such
concerns in the pediatric population (1).
Acceptance Rates for Liver Transplant
Programs
One aspect of liver program performance beginning to re-
ceive increasing attention is the rate at which organs are
accepted for transplant. Because organs are offered to pro-
grams for individuals awaiting transplantation, there are
two potentially useful metrics:
1. The rate at which organs are accepted for any candidate
at the program (organ acceptance rate)
2. The rate at which organ offers are accepted at the pro-
gram (offer acceptance rate)
For example, suppose a program is offered 100 livers
specifically for 200 individual candidates during a period.
If the program accepts 50 livers for transplant, the organ
acceptance rate is 50%, while the offer acceptance rate
is 25%. Because of differences in donor acceptance crite-
ria as well as differences in the characteristics of waiting
candidates across programs, liver organ and offer accep-
tance rates can vary substantially. Additionally, because
of the nature of offer/acceptance process and the circum-
stances under which these data are collected, acceptance
rate metrics can be difficult to interpret. The OPTN is begin-
ning to consider how such metrics may be used to monitor
program performance in conjunction with transplant rates
and waiting-list mortality rates. The SRTR is currently gen-
erating these data on a recurring basis in order to inform
both programs and the OPTN.
Acceptance and refusals: On the basis of formal OPTN
policy, deceased donor livers are offered to potential trans-
plant candidates in decreasing order of medical urgency.
It is not uncommon for programs to refuse offers for spe-
cific candidates. When this occurs, a reason for refusal
must be provided by the transplant center to the OPTN.
Typically, organs are refused for reasons such as donor
age, donor quality or positive serology, in keeping with
the specific philosophies at each transplant program. Each
program has the option to avert certain types of offers
based on prespecified acceptance criteria for the program
as a whole and for specific candidates, such as donor age,
donor weight or other specific clinical parameters. For ex-
ample, a program that sets a general limit of 60 years on
donor age would not receive offers for 65-year-old donor liv-
ers. Some programs may have liberal acceptance criteria,
and as such tend to receive a large number of offers, but
may accept fewer organs. Other programs may be more
conservative and tend to receive relatively fewer offers, but
accept many organs. Even though both types of programs
may accept the same number of organs, their acceptance
rates may be very different because of the differences in
the number and types of offers received. Additionally, the
reasons for turn down reported must accurately reflect the
reasons behind the decision.
Preliminary data: Using data generated by the SRTR,
the OPTN Membership and Professional Standards Com-
mittee has begun to investigate the use of acceptance
rates (in combination with other pretransplant measures)
as a performance metric for liver and kidney transplant pro-
grams. The goal is to identify programs that are not accept-
ing ‘good’ organs (i.e. those organs that most programs
would identify as suitable for transplant). In the current
analysis, a ‘good’ organ is defined as one that is accepted
within either the first 50 offers or the first three transplant
programs. Both an actual and expected acceptance rate is
generated for each program, with the latter rate derived
from logistic regression models of organ acceptance and
offer acceptance based on national data. A p-value provides
evidence to support the assertion that the actual accep-
tance rate is significantly different from the expected rate
(the rate predicted for that center’s caseload and offers,
based on national average acceptance behavior).
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Figure 11: Ranges in observed or-
gan acceptance rates: liver pro-
grams with >9 offers, 7/06–6/07.
Based on livers offered for transplant between July 2006
and June 2007, the overall US offer acceptance rate was
19%, and the overall US organ acceptance rate was 45%.
For transplant programs offered at least 10 organs dur-
ing that period, the offer acceptance rate ranged from 0%
to 64%, and the organ acceptance rate ranged from 0%
to 94%. Of all liver transplant programs (n = 122), the
offer acceptance rate was not statistically different from
expected in 62 programs (51% of programs). For 35 pro-
grams, the offer acceptance rate was statistically higher
than expected, whereas for 25 programs (one-fifth of all
liver programs), the offer acceptance rate was statistically
lower than expected. When organ acceptance rates were
examined, the results for 58 programs (48% of programs)
were not statistically different from expected. The results
were statistically higher than expected for one-quarter of
the programs (n = 30; Figure 11). Conversely, in approxi-
mately one-quarter of the programs the organ acceptance
rates were statistically lower than expected. The implica-
tions of having an acceptance rate that is different from
expected for program performance are not yet completely
Table 4: Liver transplants using DCD donors and number of liver transplant programs that performed DCD liver transplants by year
(1/1/2000–12/31/2007)∗
Total donors DCD donors DCD donors DCD liver transplant programs
N N % of total N
Year of transplant
2000 4407 39 0.88 11
2001 4465 68 1.52 20
2002 4697 76 1.62 28
2003 5042 110 2.18 38
2004 5459 178 3.26 42
2005 5679 260 4.58 54
2006 5849 278 4.75 60
2007 5625 295 5.24 62
Total 41 223 1304 3.16 86
∗Excludes multiorgan transplants.
understood. Given the limitations associated with the in-
terpretation of acceptance rates, the OPTN is also exam-
ining transplant rates as a program performance metric, as
preliminary results suggest a high degree of correlation be-
tween these transplant rates and organ/offer acceptance
rates. Exploratory work in this area is ongoing.
Donation after Cardiac Death (DCD) Liver
Transplantation
Use of liver allografts from DCD donors has continued to
increase steadily and now accounts for 5% of all liver-only
transplants, compared with 0.9% of transplants performed
in 2000 (see Table 4). The number of centers utilizing DCD
allografts has also increased quite markedly from 11 cen-
ters in 2000 to 62 in 2007. Possible factors contributing
to this rise include the continued critical shortage of avail-
able organs for transplantation, the report from the Insti-
tute of Medicine encouraging increased DCD organ utiliza-
tion and the efforts of the Health Resources and Services
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Table 5: Donor characteristics by deceased donor type (DCD vs. DBD) (1/1/2000–12/31/2007)∗
DBD DCD
p-Value
N Percentage N Percentage DBD vs. DCD
Total 39 919 100.0 1304 100.0
Age (years) <0.0001
Under 2 664 1.7 5 0.4
2–5 687 1.7 10 0.8
6–11 980 2.5 27 2.1
12–17 3354 8.4 121 9.3
18–39 14 252 35.7 557 42.7
40–49 7304 18.3 296 22.7
50–59 6799 17.0 215 16.5
60–69 3919 9.8 64 4.9
70 and older 1960 4.9 9 0.7
Gender <0.0001
Female 16 311 40.9 445 34.1
Male 23 608 59.1 859 65.9
Race <0.0001
White 27 734 69.5 1116 85.6
Black 5886 14.7 101 7.7
Other 1209 3.0 20 1.5
Hispanic 5088 12.7 67 5.1
Missing 2 0.0 0 0.0
Cause of death <0.0001
Anoxia 4882 12.2 381 29.2
Stroke 16 902 42.3 284 21.8
Trauma 16 985 42.5 561 43.0
Other 1139 2.9 78 6.0
Missing 11 0.0 0 0.0
∗Excludes multiorgan transplants.
Administration (HRSA) sponsored Organ Donor Break-
through Collaborative (2,3).
When compared with donation after brain death (DBD)
donors, DCD donors were more likely to be between 18 to
49 years of age (54% of DBD donors versus 66% of DCD
donors), as demonstrated in Table 5. Older donors (≥50
years) were 32% of the total number of DBD donors but
only 22% of the DCD donors (p = 0.001). This would sug-
gest that transplant centers are selectively utilizing DCD
donors in the younger adult age range, or that younger
adults are more likely to be declared dead from cardiac
death. A higher percentage of DCD donors die from an
anoxic injury than DBD donors, while stroke is reported as
the cause of death in a higher percentage of DBD donors
than DCD donors. Additional donor characteristics are pre-
sented in Table 5.
Recipients of DCD organs were more likely to be adult,
male and white and to have a higher body mass index
(BMI) and diagnosis of cholestatic cirrhosis (Table 6). The
likelihood that DCD organs came from outside the local
organ procurement organization is slightly higher than DBD
(Table 7). The mean cold ischemia time of 7.6 hours for
DCD versus 7.7 hours for DBD donors was not statistically
different (p = 0.40).
The recipients of DBD allografts were more likely to be in
the ICU at the time of transplant and were also more likely
to have MELD scores of 25 or higher (Tables 6 and 8). This
suggests that centers are selecting DCD organs for pa-
tients who are less critically ill. Alternatively, centers may
be utilizing DCD organs as an opportunity to offer trans-
plantation to patients identified as in need of a transplant,
who are at a lower priority score.
Graft survival for DCD liver allografts is inferior to DBD liver
allografts (Figure 12). This is similar to what was reported
previously (4,5). Covariates included in the graft survival
model were: all donor characteristics in Table 5; all recip-
ient characteristics from Table 6 plus waiting list status
1A/B, preexisting malignancies, history of diabetes, prior
abdominal surgery, portal vein thrombus, Hepatitis B and
C status and transplant characteristics including partial or
split liver, ABO compatibility of donor and recipient, donor
location (local, regional or national) and cold ischemia time.
A recent single-center report noted an increased incidence
of ischemic biliary complications among recipients of DCD
donors where the donor weighed more than 100 kg or was
over age 50 years, with total ischemia time of 9 hours or
more (6). We ran a model on the subset of recipients of
DCD livers only (results not shown) that confirmed a higher
risk of graft failure for livers from DCD donors weighing
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Table 6: Recipient characteristics by deceased donor type (DCD vs. DBD) (1/1/2000–12/31/2007)∗
DBD DCD
p-Value
N Percentage N Percentage DBD vs. DCD
Total 39 919 100.0 1304 100.0
Age (years) <0.0001
Under 1 915 2.3 4 0.3
1–5 1140 2.9 8 0.6
6–11 590 1.5 3 0.2
12–17 795 2.0 11 0.8
18–24 842 2.1 17 1.3
25–34 1474 3.7 31 2.4
35–44 4510 11.3 119 9.1
45–54 14 747 36.9 511 39.2
55–64 11 461 28.7 445 34.1
65 and older 3445 8.6 155 11.9
Gender 0.025
Female 13 902 34.8 415 31.8
Male 26 017 65.2 889 68.2
Race 0.0002
White 28 826 72.2 1000 76.7
Black 3797 9.5 111 8.5
Other 2141 5.4 39 3.0
Hispanic 5155 12.9 154 11.8
Body mass index <0.0001
Under 20 3827 9.6 86 6.6
20 to 24 9552 23.9 331 25.4
25 to 29 12 768 32.0 444 34.0
30 and older 11 246 28.2 417 32.0
Missing 2526 6.3 26 2.0
Medical condition <0.0001
In ICU 6776 17.0 148 11.3
Hospitalized 5939 14.9 164 12.6
Not Hospitalized 27 149 68.0 991 76.0
Missing 55 0.1 1 0.1
Mechanical support 0.08
Not on mechanical support 36 434 91.3 1217 93.3
On mechanical support 3429 8.6 86 6.6
Missing 55 0.1 1 0.1
Previous liver transplant <0.0001
No 36 426 91.2 1231 94.4
Yes 3493 8.8 73 5.6
Diagnosis <0.0001
Acute hepatic necrosis 2916 7.3 61 4.7
Noncholestatic cirrhosis 24 278 60.8 874 67.0
Cholestatic cirrhosis 3678 9.2 114 8.7
Metabolic disorders 1301 3.3 38 2.9
Malignant neoplasm 3379 8.5 128 9.8
Other 4354 10.9 89 6.8
Missing 13 0.0 0 0.0
∗Excludes multi organ transplants.
more than 100 kg and for livers from DCD donors over age
of 50 years combined with >9 hours of cold ischemia time.
The risk of graft failure did not change based on center
experience, suggesting there is not a learning curve with
the use of DCD allografts as has been seen with other
types of grafts such as living donor grafts (Table 9). Given
that DCD organ recovery is technically similar to DBD or-
gan recovery, other than the need to rapidly cannulate and
flush, it is not surprising to observe the lack of a learning
curve.
Living Donor Liver Transplantation
Living donor liver transplantation continues to play a
small but important role in the management of patients
with cirrhosis and even fulminant liver failure. While the
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Table 7: Transplant characteristics by deceased donor type (DCD vs. DBD) (1/1/2000–12/31/2007)∗
DBD DCD
p-Value
N Percentage N Percentage DBD vs. DCD
Total 39 919 100.0 1304 100.0
Donor location 0.005
Shared 12 549 31.4 458 35.1
Local 27 370 68.6 846 64.9
ABO compatibility 0.0003
Compatible 3125 7.8 64 4.9
Incompatible 311 0.8 7 0.5
Identical 36 483 91.4 1233 94.6
Mean SD Mean SD
Cold ischemia time 7.7 3.6 7.6 3.5 0.40
∗Excludes multiorgan transplants.
total number of candidates waiting for deceased donor
liver transplants stopped climbing following the institution
of MELD/PELD in 2002, the number of liver transplant
candidates has remained relatively constant over the past
5 years, with 16 438 candidates awaiting transplant at the
end of 2007 (including inactive candidates) [Table 1.3]. Con-
comitant with the stabilization of the number of candidates
awaiting liver transplantation, there was a steady increase
in the number of deceased donor livers recovered between
2000 and 2006 (5081 recovered organs in 2000 and 7084
recovered organs in 2006) [Table 1.2]. These two trends
certainly suggest an improvement in the balance between
supply of deceased donor livers and demand for liver trans-
plantation in the US. In 2007, however, the steady rise in
the recovery of deceased donor livers may have reached
a plateau, as slightly fewer livers (7029) were recovered in
2007 than in 2006 [Table 1.2]. Should a new equilibrium
have been reached, centers may re-examine the role of liv-
ing donor liver transplantation in managing liver transplant
candidates.
Characteristics of LDLT recipients: While the total num-
ber of living donor liver transplants peaked in the US in
2001 with a total of 522 cases [Table 9.4b] among 67 dif-
ferent centers, a number of transplant centers continue
to perform the procedure on a regular basis, including 40
centers with at least one living donor transplant in 2007.
Table 8: Distribution of MELD/PELD score at transplant by de-
ceased donor type (DCD vs. DBD) (9/1/2001–12/31/2007)
DBD DCD
N Percent N Percent
MELD/PELD at transplant
Under 10 3967 12.2 143 11.7
10–14 6070 18.7 274 22.4
15–19 7466 23.0 321 26.2
20–24 5474 16.9 219 17.9
25–34 5773 17.8 171 14.0
35 and higher 3698 11.4 95 7.8
Total 32 448 100.0 1223 100.0
Since 2002, between 266 and 363 living donor liver trans-
plants have been performed annually. Approximately 20%
of these cases have been performed in pediatric recipients,
a percentage that has held steady since 2001 [Table 9.4b],
with the bulk of the remainder of cases involving recipients
aged 35 years and older. While the great majority of LDLTs
have been performed for managing chronic liver disease,
a small number of LDLTs continue to be performed for
managing acute liver failure, with 15 such cases occurring
in 2006 and nine cases performed for acute liver failure in
2007 [Table 9.4a]. A recent review from the National In-
stitutes of Health funded Adult-to-Adult Living Donor Liver
Transplantation (A2ALL) Living Donor Liver Transplant Con-
sortium described the detailed LDLT experience in a num-
ber of centers and found that survival rates for these cen-
ters mirrored those in Asia, where LDLT is a much more
common approach to the management of acute liver failure
(7,8).
In the US, LDLT is typically done for relatively healthy trans-
plant candidates, with 68% of LDLT recipients in 2007 hav-
ing a MELD/PELD score at transplant of less than 30 and
the great majority of those patients having a MELD/PELD
score of less than 20 [Table 9.4b]. Since LDLT typically oc-
curs at a lower MELD score than DDLT, receipt of an LDLT
usually shortens the candidate’s time waiting for transplant
and thus lowers the risk of mortality on the waiting list
(9). The majority of LDLT recipients are transplanted from
home (79% of LDLT recipients compared with 70% of
DDLT recipients in 2007). Conversely, very few LDLTs are
currently being performed for patients on mechanical sup-
port (2% of LDLT recipients compared with 6% of DDLT
recipients in 2007) or for ICU patients (6% of LDLT re-
cipients compared with 13% of DDLT recipients in 2007)
[Table 9.4a, 9.4b].
Outcomes following living donor liver transplanta-
tion: While recent reports suggest enhanced waiting
list survival with the pursuit of LDLT (9,10) compared
with waiting for a DDLT, one must also consider LDLT in
the context of posttransplant outcomes. Analysis of data
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Figure 12: Adjusted graft survival
for DCD and DBD liver transplants,
9/1/2001–3/31/2006.
accumulated in the OPTN/SRTR database shows that both
short-term and long-term patient survival is quite similar
between recipients of LDLT and DDLT. Adjusted LDLT re-
cipient 3-month survival has been 95% from 2000 to 2002
and 97% from 2003 to 2006 [Table 9.13b]. Longer-term
follow-up on relatively large numbers of living donor liver
transplant recipients is now becoming available, so that
5-year adjusted patient survival for LDLT is estimated at
78% (±1.1%) [Table 9.12b], compared with 5-year survival
for DDLT in the same cohort of 73% (±0.6%), although
these estimates are not adjusted for MELD score at trans-
Table 9: Risk of graft failure by DCD case number within each
center by five-case increments among DCD transplants n = 1000
(9/1/2001–3/31/2007)
Number 95%
Center case of Hazard confidence
numbers transplants ratio∗ interval p-Value
Cases 1–5 262 1.11 (0.78, 1.57) 0.56
Cases 6–10 165 1.11 (0.75, 1.64) 0.60
Cases 11–15 117 1.17 (0.78, 1.78) 0.45
Cases 16–20 83 0.92 (0.57, 1.47) 0.72
Cases 21–25 73 0.86 (0.52, 1.45) 0.58
Cases 26–30 48 0.82 (0.45, 1.50) 0.52
Cases 31–35 38 1.09 (0.59, 2.00) 0.78
Cases 36+ (ref) 214 1.00 Reference
∗Adjusted for donor age, donor cause of death, donor race, donor
sex, donor height, recipient age, recipient sex, recipient diabetes,
recipient race, recipient diagnosis, recipient medical condition
at transplant, pretransplant dialysis, pretransplant mechanical
support, recipient history of malignancy, recipient previous
abdominal surgery, recipient body mass index, previous liver
transplant, recipient MELD/PELD or Status 1/A/B at transplant,
recipient history of portal vein thrombosis, recipient hepatitis B
positive, recipient hepatitis C positive, blood type compatibility,
regional/national transplant, cold ischemia time and partial/split
liver transplant.
plant [Table 9.13a]. While a number of patient character-
istics may influence these assessments of outcomes, it
does appear that posttransplant survival after LDLT is quite
comparable to that achieved following DDLT. This favorable
transplant experience, however, must be balanced by the
theoretical and real risks accrued by the healthy donors
who are involved in the LDLT process (11).
MELD/PELD Exceptions
Deceased donor liver allografts are currently allocated ac-
cording to MELD score for those >12 years old and PELD
score for those <12 years old. This scoring system has
been shown to predict 3-month pretransplant mortality
with a reasonably high degree of accuracy. This scoring
system is most accurate when the liver failure itself is
likely to cause death in the near future. There are a num-
ber of medical conditions concomitant with end-stage liver
disease where the condition itself is more likely to lead to
death than the liver failure. The presence of these ‘excep-
tion’ cases was identified early in the development of the
MELD (12). The most common of these conditions is HCC,
where the threat to mortality from cancer metastasizing is
greater than that of near-term liver failure. There is a mul-
titude of other disease entities that have similar charac-
teristics. One common theme is the role of nonmortality
endpoint for these diseases (such as metastasis), which
differs from the mortality endpoint for the majority of pa-
tients. A systematic process was developed for assigning
MELD exception points for HCC patients, approved as al-
location policy by the OPTN, and implemented with the
MELD system in 2002. Patients that did not meet prede-
fined criteria (e.g. the Milan criteria for HCC) were referred
to regional review boards (RRB) for adjudication through a
peer-review process. This process has evolved over time
but remains decentralized, so that each of the 11 OPTN
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Figure 13: Waiting list status at
time of deceased donor liver trans-
plant.
regions maintains their own RRB. Each region’s RRB has
representation from each transplant program in the region
and develops mutually agreed-upon criteria for exception
applications. Since these criteria vary by region, there is
a common perception that regions differ in their leniency
in approving applications. These perceived inconsistencies
led the OPTN to convene a study group (the MELD Ex-
ceptional Case Study Group, MESSAGE) and a consensus
conference in March 2006 (13). Seventeen exceptional
medical conditions frequently encountered by RRBs were
researched and discussed in a national consensus-building,
evidenced-based format. The findings were disseminated
to help both transplant professionals and the public under-
stand reasons for adjusting MELD scores to better reflect
the severity of these illnesses and guidelines for these
adjustments. The results of that meeting have been imple-
mented in varying degrees across the OPTN regions.
We examined MELD exceptions in place at the time of
transplant over the last 5 years. Figure 13 shows the wait-
ing list status at the time of transplant for all DDLT re-
cipients between 2003 and 2007 [Table 9.4a]. Over the 5
years, there was a slight increase in the percentage of pa-
tients receiving a DDLT with a MELD/PELD exception other
than HCC from 7.6% in 2003 to a high of 9.0% in 2005 to
8.6% in 2007. Patients transplanted with HCC exceptions
represented between 13% and 15% of total transplants.
Figure 6, described previously, shows the fraction of adult
(aged 18 and older) candidates on the waiting list that died
prior to transplant (left panel) or received a transplant (right
panel) within 30, 60 and 90 days of the snapshot date
by their waiting list status on the snapshot date, January
1, 2007 [Table 9.2b]. Within 90 days, 39% of candidates
with exceptions granted for conditions other than Stage
T2 HCC had received a transplant compared with 4% of
those without exceptions who had MELD scores under
20, 39% of those with MELD 21–30, 54% of those with
MELD 31–40 and 54% of candidates with HCC exceptions
for Stage T2 at snapshot. Only 2.4% of candidates with
MELD exceptions for conditions other than HCC on Jan-
uary 1, 2007 had died within the following 90 days. The
fraction of candidates without MELD exceptions at snap-
shot who died within 90 days varied according to their
MELD score as expected; 1.5% for MELD less than 20,
7.4% for MELD 21–30 and 13.5% for MELD 31–40. Only
1.1% of those with MELD exceptions for Stage T2 HCC
died within 90 days. Annual death rates per 1000 patient-
years at risk are shown in Table 10 [Table 9.3]. The death
rates of patients with exceptions for conditions other than
HCC are consistently comparable to those of patients with
MELD scores of 15–20.
To examine patterns of exception use in more detail, we
divided the exceptions into those for HCC, those for other
standardized conditions where criteria are delineated in
OPTN Policy and those for nonstandardized conditions that
are reviewed on a case-by-case basis by the RRB. Figure 14
shows the national use of these three types of excep-
tions among DDLT recipients across time. The fraction of
Table 10: Annual liver waiting list death rates per 1000 patient-
years at risk by status, 2003–2007
2003 2004 2005 2006 2007
MELD score, no exceptions
6–10 38 37 36 36 35
11–14 72 68 72 66 69
15–20 157 166 154 141 125
21–30 794 739 721 722 596
31–40 4978 4969 4581 3828 3758
With MELD score exceptions
HCC stage T2 126 173 151 133 99
Non-HCC exceptions 117 97 133 101 81
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None HCC Case-by-Case Standardized Diagnoses
Source: SRTR Analysis. Data as of August 2008.
Figure 14: Fraction of DDLT with
MELD/PELD exceptions by type and
year, 2002–2007.
DDLT recipients with MELD/PELD exceptions in place at
the time of transplant has increased from 23% in 2002 to
30% in 2007. The majority of exceptions are granted for
HCC, about two-thirds of the total for 2003–2007, while
it was slightly higher in 2002 (75%). Exceptions granted
on an individual, case-by-case basis have accounted for
roughly one-quarter of all exceptions, while those for stan-
dardized conditions other than HCC have been between
7% and 11% across time and were 10% of all excep-
tions in 2007. The variability by region regarding the use
of these three types of exceptions is displayed in Figure
15. In 2007, the percentage of patients transplanted with
exceptions scores ranged from 38% (regions 1 and 5) to
22% (region 3). The fraction of patients transplanted with






























Any Exception HCC Case-by-Case Standardized Diagnoses
Source: SRTR Analysis. Data as of August 2008.
Figure 15: Fraction of DDLT with
MELD/PELD exceptions by type and
region, 2007.
gions (16% in region 3, 17% for regions 7, 10 and 11,
19% for region 8), between 20% and 25% for three re-
gions (20% for region 9, 21% for region 2 and 24% for
region 4), to over 25% of total DDLT for 2007 for three
regions (26% for regions 5 and 6 and 27% for region 1).
Patients transplanted with case-by-case exceptions were
between 4% and 10% of all DDLT in 2007 (4%: region
3; 5%: 7; 6%: 1; 7%: 5, 6, 9, 11; 8%: 2, 4, 8; 10%: 10).
Exceptions for standardized conditions other than HCC ac-
counted for between 2% and 4% of all DDLT within re-
gions in 2007 (2%: regions 3, 4, 6; 3%: 2, 7, 8, 10; 4%:
1, 5, 9, 11).
Figure 16 shows the three subtypes of HCC exceptions
at two points in time—soon after the start of the MELD






























Stage T1 Stage T2 Does Not Meet Policy, RRB Reviewed
2003 2007
Source: SRTR Analysis. Data as of August 2008. In 2007, the T1 HCC exception is for 
those with AFP > 500 ng/ml and rising, with no evidence of tumors upon imaging.
Figure 16: Fraction of DDLT with
MELD/PELD exceptions for HCC by
type and region, 2003 and 2007.
system in 2003 and the most recent year of data, 2007. In
2003, there was an exception for candidates with HCC tu-
mors that were Stage T1 (14) or with chronic liver disease,
a rising alpha-fetoprotein (AFP) level of 500 ng/mL or higher
and no evidence of a tumor based on imaging studies. By
2007, the exception for Stage T1 lesions was discontinued,
but those with rising AFP still qualified for the exception.
The exception for candidates with Stage T2 HCC meeting
the Milan criteria (15) has been granted without review
by the RRBs since May 2003. Increasingly, programs are
transplanting patients with HCC that are beyond Milan cri-
teria. These candidates can receive increased MELD prior-
ity through an HCC exception application that is reviewed
prospectively by the RRB, which is also true of any can-
didate with HCC that does not meet the requirements of
OPTN Policy 4.6.4.4. These trends are evident in Figure 16,
which shows virtually no T1 HCC transplants in 2007, yet
an increasing number of HCC patients transplanted with
prospectively reviewed RRB exceptions.
Standardized exceptions for conditions other than HCC are
utilized in situations where the transplant community has
implemented guidelines in OPTN policy to allow the can-
didate to have sufficient priority to be transplanted. To a
large extent, these are conditions where the MELD score
alone does not reflect the risk of mortality or when there
are other considerations not related primarily to the risk of
mortality. They include familial amyloidotic polyneuropathy,
hepatopulmonary syndrome (including portpulmonary hy-
pertension), primary oxaluria, inborn errors of metabolism,
hepatoblastoma and hepatic artery thrombosis after liver
transplantation. Patients meeting predefined criteria for
these conditions are granted automatic exception points,
similar to the approach utilized in patients who meet Milan
criteria for HCC. Between 2002 and 2007 the number of
DDLT recipients with exceptions in place were: 623 for hep-
atopulmonary syndrome; 126 hepatic artery thrombosis
after transplant; 100 for metabolic disorders; 89 for famil-
ial amyloidosis; 77 for hepatoblastoma and 50 for primary
oxaluria. For 2007, after implementation of new OPTN Pol-
icy following the MESSAGE meeting, the number of cases
were: 116 for hepatopulmonary syndrome and portopul-
monary hypertension; 47 for hepatic artery thrombosis af-
ter liver transplantation; 27 for pediatric hepatoblastoma;
18 for metabolic disorders; 15 for primary oxaluria and 14
for familial amyloidosis. Figure 17 shows the proportion
of DDLT by OPTN region that were performed for these
conditions from 2002 to 2007.
Figure 18 shows the third group of MELD/PELD excep-
tions, those applied for and granted on a case-by-case ba-
sis with prospective review by the RRB, by region at three
points in time—2003, 2005 and 2007 (these data are pre-
sented as fractions of total deceased donor transplants in
the region, over the specified time frame). Over the period,
the fraction of each region’s total DDLT with case-by-case
exceptions has become more similar. In 2003, the frac-
tion of regional DDLT with case-by-case exceptions ranged
from 2% to 21%, with five regions between 2% and 5%,
five regions between 6% and 10% and one region above
10%. By 2005, the range was 4–15%, with only one region
with less than 5% and one region with more than 10%; the
other nine were between 5% and 9%. In 2007, all regions
were between 5% and 10%, except for region 3 with 4%.
Intestine Transplantation
Intestine transplantation continues to demonstrate ongo-
ing progress in both patient and graft survival, graft func-
tion and quality of life after transplantation. Increasing suc-
cess, however, has led to new challenges such as deter-
mining the optimal timing of referral and transplantation,
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Source: SRTR Analysis. Data from 2002-2007 combined, as of August 2008.
Figure 17: Types of standardized
diagnoses MELD/PELD exceptions
by region, 2002–2007.
the best allocation and severity of illness scoring and how
to most effectively reduce the unacceptably high waiting
list mortality rates, brought on by increasing demand and
insufficient availability of intestine grafts. Assessing long-
term outcomes can suggest directions for improvement.
This section will summarize five key areas of intestine
transplantation: waiting list mortality; donor characteristics;
transplant incidence; trends in immunosuppression and pa-
tient and graft outcomes.
Intestine candidate selection and waiting list: Intes-
tine transplant candidates typically suffer from irreversible
intestinal dysfunction and dependence on total parenteral
nutrition (TPN), often complicated by TPN-associated liver
failure or cholestasis, loss of vascular access for TPN due



























Source: SRTR Analysis. Data as of August 2008.
Figure 18: Case-by-case MELD/
PELD exceptions by region and se-
lected years.
or dehydration (16,17). The specific diagnosis and extent of
liver damage influences whether candidates are listed for
isolated intestine transplants or also listed for liver trans-
plant to receive a combined liver–intestine graft. Candi-
dates on the waiting list for intestine transplantation have
increased in number from 93 in 1998 (65 active and 28 inac-
tive) to 222 in 2007 (169 active and 53 inactive). However,
for the first time since 2003, the total number of active pa-
tients on the waiting list at the end of the year decreased in
2007 compared with 2006 (Figure 19) [Table 1.3]. The ma-
jority of active intestine candidates are children <5 years
old (63%) (Figure 20) [Table 10.1a]. The majority has a pri-
mary diagnosis of short gut syndrome (56%) compared to
32% with other diagnoses and 11% with functional bowel
problems. Similar to prior years, most candidates were
white (60%), male (61%) and had blood type O (42%).

































Source: 2008 OPTN/SRTR Annual Report, Table 10.1a.  
Figure 19: Number of candidates
on the intestine waiting list, active
at year-end, 1998–2007.
However, there has been a trend of an increasing frac-
tion of the waiting list being African American. Since a low
of 14% in 2002, this fraction has increased over time to
23% in 2007. In 2007, 8% of active waiting list candidates
had received a previous intestine transplant, down from
2006 when 12% of candidates had a previous intestine
transplant.
These patients spend a significant amount of time on the
waiting list. At the end of 2007, 23% had spent between
1 and 2 years on the waiting list and 20% had spent more
than 2 years [Table 10.1a]. Median TT decreased signif-
icantly in 2007 to 159 days compared with 257 in 2006
(Figure 21) [Table 10.2]. Discrepancies appear to exist in
waiting time across age groups, although the limited sam-

































Source: 2008 OPTN/SRTR Annual Report, Table 10.1a.  
Figure 20: Number of candidates
on the intestine waiting list by age,
at year-end, 1998–2007.
evaluate whether these discrepancies reflect true differ-
ences or are due to imprecision in the estimates. Adults
aged 18–34 and 35–49 years waited a median TT of 77 and
28 days, respectively, while children <1 year old and 1–5
years old waited a median time of 321 and 214 days, re-
spectively. Compared with the overall population in 2007,
African Americans and Hispanic candidates waited longer,
with a median TT of 250 and 447 days, respectively.
Overall outcomes at 1 year after being listed for intestine
transplant have been relatively stable with some notable
exceptions. Table 11 shows waiting list outcomes at 1 year
after listing, grouped by year of listing. Among candidates
added to the waiting list in 2006 (n = 312), 54% of patients
had been transplanted within 1 year of listing, with 17% re-
ceiving an isolated intestine transplant and 37% receiving
926 American Journal of Transplantation 2009; 9 (Part 2): 907–931

























Source: 2008 OPTN/SRTR Annual Report, Table 1.5.  
Figure 21: Median time to trans-
plant (TT) for new intestine wait-
ing list registrations, 1998–2007.
a multiorgan transplant. The number of patients receiving
multiorgan transplants within 1 year of listing increased
from 29% in 1998 to 37% in 2006. This may indicate that
need for timely referral must continue to be emphasized
in order to optimize chances for intestine adaptation and
lower the number of patients who ultimately develop par-
enteral nutrition associated irreversible liver disease requir-
ing transplant. About one-fifth of those added to the list
for an intestine transplant in 2006 (21%, n = 66) were still
on the waiting list 1 year later. Of those still waiting, 55%
were listed at Status 1 (12% of all 2006 new listings), 20%
were not Status 1 (4% of all 2006 new listings) and 26%
were inactive (5% of all 2006 new listings).
Slightly more than one-quarter (26%) of those added to the
waiting list in 2006 had been removed within 1 year with-
out receiving a transplant. For candidates removed from
Table 11: Outcomes at 1 year after listing for candidates on the intestine transplant waiting list, 1998–2006
Year of listing
1998 1999 2000 2001 2002 2003 2004 2005 2006
Total listings during calendar year (N) 146 132 155 210 195 196 244 275 312
Status 365 days after listing (%) 100 100 100 100 100 100 100 100 100
Still on waiting list 15 23 23 21 16 18 18 19 21
Status 1 4 11 13 11 9 11 10 10 12
Not status 1 4 7 5 6 4 3 3 3 4
Inactive 7 5 5 4 3 4 5 6 5
Received transplant 47 49 52 51 50 52 56 54 54
Intestine alone transplant 18 17 20 22 19 21 21 17 17
Multiple organ 29 32 32 29 31 31 35 37 37
Died within 1 year of listing 27 23 18 20 24 22 18 18 17
Condition worsened/medically unsuitable 3 4 1 1 2 2 2 6 5
No record of subsequent death 2 2 0 1 1 1 0 2 2
Died after removal as too sick 1 2 1 0 1 1 2 4 3
Condition improved 1 0 3 2 3 3 3 2 2
Removed for other reasons 6 3 5 4 5 4 2 1 2
the list, two-thirds had died within the year (67% of re-
movals), which equates to 17% of all candidates listed for
intestine transplant in 2006. This is an improvement from
previous years; among those listed in 1998, 27% died with-
out a transplant within 1 year of listing. The other third
of the removals among those listed in 2006 were coded
as too sick (n = 14), condition improved (n = 5) or other
(n = 7).
Despite overall improved TT, waiting list mortality (ex-
pressed as the death rate per 1000 patient-years at risk)
remains the highest among all solid organ transplant re-
cipients (Figure 22) [Table 1.6]. The current death rate for
intestine transplant candidates is 226, which, although dra-
matically better than the rate of 583 reported in 1998,
remains higher than all other transplant candidates in-
cluding those awaiting kidney (65), liver (113), lung (126),
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Source: 2008 OPTN/SRTR Annual Report, Table 1.5.  
Figure 22: Unadjusted death rates
per 1000 patient-years at risk for
patients on the waiting list by or-
gan, 1998–2007.
heart (142) and heart/lung (195) transplantation. Waiting list
death rates are highest among patients aged 35–49 years
(437), 50–64 years (400) and those <1 year of age (368)
compared with relatively low annual death rates for those
age 12–17 years (55) [Table 10.3]. Death rates improved
from 349 to 228 in children aged 1–5 years. Overall higher
death rates were seen in white candidates (267) and those
with blood type B (282). Patients with functional bowel
problems had the lowest death rate among the diagnosis
groupings (65).
There are ongoing efforts to address the significant mor-
tality rate facing intestine transplant candidates through
refinements in allocation policy (14). The first of these
changes was in March 2003 and provided combined liver
and intestine candidates additional MELD/PELD points
equivalent to 10% mortality risk at 3 months (Policy
3.6.4.7). This policy allowed the liver to be placed off the in-
testine list if there were no suitable regional Status 1A/1B
liver candidates (policy 3.11.4) and allocated pediatric
donor organs age 0–10 years to pediatric recipients after
Status 1A/1B liver candidates were offered the organ. This
MELD risk adjustment, however, had been shown to ade-
quately predict mortality in adults but was not as accurate
for combined liver–intestine candidates, who were mostly
children. As a result, in January 2007 an additional 23 extra
PELD points were allocated to combined liver and intes-
tine candidates under age 18 years (Policy 3.6.4.7). More
recently, policy changes have been approved to allocate
combined liver and intestine grafts according to the intes-
tine match run after the liver graft has been sequentially of-
fered though national Status 1A and 1B offers. Any impact
of these allocation changes should be apparent in the near
future.
Intestine donation: Intestine donation and acceptance
patterns must also be improved to reduce waiting list
mortality. Unfortunately, these practices appear relatively
static. Although the 205 intestine donors utilized in 2007
is the most ever, the increase over the previous year (185)
was only 11% [Table 1.1]. Of note, after a peak incidence
of seven live intestine donors in 2005, only one live intes-
tine donor was utilized in 2007. The percentage of intes-
tine donors recovered from deceased donors with at least
one organ recovered increased from 1.3% (68 of 5793) in
1998 to 2.5% (205 of 8091) in 2007 [Table 2.16]. Intestinal
recovery was always associated with recovery of other or-
gans, usually intestine and kidney or pancreas only (27%)
or intestine and other combinations (68%) [Table 2.16].
Only 17% of intestines recovered from deceased donors
in 2007 were used locally, highlighting both the relatively
small number of intestine transplant programs, as well
as the efforts that are taken to secure suitable donors
[Table 3.10].
Only seven of the 205 recovered intestines were not used
(a discard rate of 3%) [Table 3.10]. On the other hand,
the most frequently reported reasons for nonrecovery of
consented intestine donors included ‘no recipient found’
(33%), ‘poor organ function’ (29%), other (20%) and ‘donor
medical or social history’ (12%) [Table 3.12]. Most intestine
donors were children, with 26% being <1 year old and
22% being between 1 and 5 years of age [Table 2.5]. The
most common demographic and medical characteristics
of intestine donors were: white race (58%); male (66%);
blood type O (58%) and head trauma as cause of death
(55%). There have been no intestine donors after cardiac
death since an isolated case in 2003. While donors <1 year
are often considered with caution, it is noteworthy that the
death rate for the first year posttransplant for recipients
who received a graft from an infant donor fell to 248 in 2006
compared with 379 in 2004 and 364 in 2005, highlighting
the utility of this potentially underutilized donor age group
[Table 10.7].
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Intestine recipients: In 2007, 198 patients received a
transplant that included an intestine graft, the most ever
in 1 year [Table 10.4]. This corresponded to an inci-
dence of intestine transplant (IT) of 0.66 per million pop-
ulation in 2007 with the highest incidence across age
groups being for the <1 year age group [Table 10.5].
The most frequent categories of demographic and medical
characteristics among IT recipients in 2007 were: children
aged 1–5 years (28%); white race (69%) and short gut
syndrome (72%). Ten percent of IT recipients in 2007 had
received a previous IT. Recipients of intestine-only grafts
were 29% of all IT recipients (n = 57), while the majority
(n = 141) received intestine-containing multiorgan grafts,
usually with the liver (n = 33) or liver–intestine–pancreas
(n = 88) but also with kidney (n = 2), pancreas–intestine
(n = 4) or kidney–pancreas–liver–intestine (n = 14). The
number of isolated intestine grafts has remained stable for
the past 2 years, while the number of IT recipients also
receiving the liver has increased by 30%, from 104 to 135.
One can speculate that despite an increasing awareness
of IT, most patients still undergo IT requiring a liver follow-
ing TPN-induced liver failure rather than isolated ITs prior
to liver failure. Optimal timing for referral and evaluation is
still being determined.
Primary payment sources for IT were private insurance
(41%), Medicaid (44%), Medicare (9%) and other (6%).
Most IT recipients (70%) were not in the hospital when
the intestine graft became available, a factor that the In-
ternational Intestine Transplant Registry has found to be
associated with improved outcomes (18).
Immunosuppression: Immunosuppression following in-
testine transplantation continues to evolve. Primary induc-
tion therapy continued to be common in ITs in 2007 but
not universal, with 51% having no induction therapy used
[Table 10.6a]. The use of induction therapy has varied from
1998 to 2007, starting at 41% in 1998, peaking at 75%
in 2003 and declining to 49% in 2007. In 2007, the most
common agent, used alone or in combination, was rab-
bit antithymocyte globulin (ATG; Thymoglobulin, Genzyme
Corp., Cambridge, MA) used in 24% of all IT recipients,
followed by muromonab-CD3 (Orthoclone OKT3, Ortho
Biotech, Bridgewater, NJ) used for 18% of recipients, alem-
tuzumab (Campath-1H, Genzyme Corp., Cambridge, MA)
used for 13% and daclizumab (Zenapax, Roche Group, Nut-
ley, NJ) used 9%. In 1998, induction therapy was used in
only 41% of IT recipients, almost all of which used da-
clizumab. This change to induction therapy and its resul-
tant positive impact on survival have also been noted by
the global intestinal transplant community, as reported by
the International Intestine Transplant Registry (18).
Immunosuppression used for maintenance prior to dis-
charge includes corticosteroids in 77% of IT recipients, the
calcineurin inhibitor tacrolimus (Prograf, Astellas, Tokyo,
Japan) in almost all IT recipients (97%), and antimetabolite
use in 23%, mostly mycophenolate mofetil (MMF; Cell-
Cept, Roche Group, Nutley, NJ) [Table 10.6e]. The most
common specific regimen in 2007 was tacrolimus and
steroids (56%), followed by tacrolimus alone (11%) and
tacrolimus with MMF or mycophenolate sodium (MPA)
[Table 10.6d]. The most common maintenance regimen at
1 year posttransplant was tacrolimus and steroids (47%),
followed by tacrolimus alone (33%) [Table 10.6f]. By 1 year,
the incidence of patients off steroids completely had in-
creased to nearly 40% [Table 1.9a].
Acute rejection treated with antirejection medications at
any time between transplant and the 1-year follow-up re-
port occurred in 61 of 175 cases in 2006, an incidence of
35% [Table 10.6i]. This is a decrease from 68% in 1997 but
is about the same as 2005 when it was 33%. Steroids were
used in 82% of these acute rejection episodes, and anti-
bodies were used in two-thirds of these reported episodes.
This represents an increase in antibody use to its highest
level since 1997; antibody use was 40% in 2005 and 46%
in 2004. The most common antibody utilized in 1997–2006
remained muromonab-CD3 (41%), followed by rabbit ATG
(15%).
Intestine transplant recipient survival: Patient and graft
survival, as well as death rates per 1000 patient-years at
risk, appear to have reached somewhat of a plateau de-
spite significant improvements compared with 1997. For
example, 1-year adjusted graft survival for intestine recipi-
ents was 70% (±3.6%) for 2006, which is not statistically
different from adjusted graft survival for any year between
2000 and 2006 [Table 1.11a]. However, it is better than
adjusted 1-year graft survival from 1997 to 1999. One-year
adjusted patient survival for IT recipients (isolated intes-
tine or intestine-containing multiorgan) was 78% in 2006,
which again is not statistically significantly different than
that for 2000–2005 but is a significant increase from 60%
in 1997 [Table 1.12a].
Figure 23 shows the unadjusted graft and patient survival
for IT recipients of intestine-only grafts and combined liver–
intestine grafts, at several follow-up time periods. Among
recipients of intestine-only grafts, unadjusted patient sur-
vival was always higher than graft survival [Table 1.13]. At
3 months after transplant, graft survival was 83% and pa-
tient survival was 94%. Graft survival was 68% at 1 year,
57% at 3 years, 36% at 5 years and 25% at 10 years.
Patient survival followed a similar pattern and was 81%
at 1 year, 71% at 3 years, 56% at 5 years and 46% at
10 years. For recipients of combined liver–intestine grafts,
patient and graft survival were statistically the same. Pa-
tient survival declined from 88% at 3 months, 73% at
1 year, 61% at 3 years, 55% at 5 years and 38% at
10 years. Isolated intestine 10-year graft survival is not sta-
tistically different from that of pancreas-alone, lung-alone
and heart–lung transplants but lags significantly behind that
of other organ transplants. As would be expected given the
possibility of graft removal and the current technology of
organ replacement therapies, 10-year patient survival for
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Source: 2008 OPTN/SRTR Annual Report, Table 1.13. 
Figure 23: Unadjusted patient and
graft survival for intestine-alone
and liver-intestine recipients.
intestine-only recipients (46%) is greater than that of lung-
alone (28%) and heart-lung recipients (28%), but less than
that of pancreas-alone transplants (73%).
Overall, the 1-year posttransplant unadjusted death rate
per 1000 patient-years at risk for intestine recipients trans-
planted in 2006 was 269, similar to the death rate of 253
for those transplanted in 2005 [Table 10.7]. Those <1 year
of age had the highest posttransplant death rate of 511
for those transplanted in 2006. Other characteristics with
higher death rates than the overall death rate were: being
African American (417) and being Hispanic (398). Although
absolute numbers were small, the percentage of deaths
among patients on mechanical support at the time of trans-
plant have been excessive since 1998 when 71% (5 out of
7) died within 1 year of transplant. The lowest was 40%
(2 deaths out of 5 recipients) in 2001 and the highest was
75% in 2006 (3 deaths out of 4 recipients). When evaluated
by hospitalization status at the time of transplant, those in
the ICU had a death rate of 737 compared with 310 for
those in the hospital but not in the ICU and 197 for those
not hospitalized.
Importantly, there were 584 recipients living with a func-
tioning graft at the end of 2006; 44% had been transplanted
when they were <5 years old and 6% had received more
than one IT [Table 10.16].
Summary and Implications: Improving success with
intestine transplantation has been notable over the past
10 years. However, several key issues arose upon re-
view of this year’s summary analysis: First, the increas-
ing number of patients with functioning grafts will cause
a shift of focus from short-term patient survival to opti-
mizing long-term outcomes. Increasingly, causes of pa-
tient and graft loss such as chronic rejection will come
under scrutiny with a focus on immunosuppression and
research directed towards improving long-term outcomes.
The fact that patient and graft survival has stabilized over
recent years suggest that efforts must now be intensi-
fied to identify ways to improve results for patients. This
could include a focus on intestinal rehabilitation, appropri-
ate patient selection and developing broadly agreed upon
criteria for the timing of referral and transplantation. Finally,
the transplant community must continually reassess its ef-
forts to improve waiting list mortality in this at-risk popula-
tion, especially in the very young. The goal of eliminating
death on the waiting list is achievable by modest increases
in the recovery of intestine-containing grafts and better
allocation.
Conclusion
Overall, progress continues in liver and intestine transplan-
tation. Refinements in allocation have resulted in signifi-
cant improvement in our ability to direct the available or-
gans to those most in need. Though not perfect for all,
MELD and PELD have offered a significant improvement
in our ability to determine need, and the numbers of pa-
tients being transplanted via the nonstandard exception
mechanism appears stable.
Efforts to increase the pool of potential donors through the
prudent use of living donors, broad-based education efforts
such as the Collaborative and initiatives to evaluate donors
previously underutilized (such as DCD and infant donors)
will hopefully contribute to narrowing the gap between
the number of patients who might benefit from trans-
plantation and the available donor supply. A better under-
standing of organ acceptance practices may provide addi-
tional opportunities to improve donor utilization. Ultimately,
organ acceptance practices must also be considered in
the context of patient outcomes, both before and after
transplantation.
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